Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): A paradigm for understanding leukaemogenesis?

British Journal of Haematology

Volumn 128, Issue 1, 2005, Pages 18-34

  Reilly, John T ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Acute myeloid leukaemia; c KIT; Core binding factor; Core binding factor MYH11; Pathogenesis

Indexed keywords

CORE BINDING FACTOR; FLT3 LIGAND; IMATINIB; MYOSIN HEAVY CHAIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; RAS PROTEIN; RETINOIC ACID; STEM CELL FACTOR; TRANSCRIPTION FACTOR RUNX2;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME 16; CHROMOSOME INVERSION; CHROMOSOME INVERSION 16; CORE BINDING FACTOR BETA GENE; ENZYME ACTIVATION; FUSION GENE; GENE DUPLICATION; GENE INSERTION; GENE MUTATION; GENE SILENCING; HUMAN; HYPOTHESIS; LEUKEMOGENESIS; MYH11 GENE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ACUTE DISEASE; ANIMALS; CHROMOSOMES, HUMAN, PAIR 16; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID; MODELS, GENETIC; ONCOGENE PROTEINS, FUSION;

EID: 12744253468     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05236.x     Document Type: Review

References (188)

1. Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Gari, M.A, Peake, I.R., Rees, D.C., Vandenberghe, E.A., Winship, P.R. & Reilly, J.T. (2000) FLT3 internal tandem duplication mutations in adult myeloid leukaemia define a high risk group. British Journal of Haematology, 111, 190-195.
2. Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A, Care, R.S., Peake, I.R. & Reilly, J.T. (2001a) Genomic structure of human FLT3: implications for mutational analysis. British Journal of Haematology, 113, 1076-1077.
3. Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Care, R.S., Peake, I.R. & Reilly, J.T. (2001b). Identification of novel FLT3 Asp835 mutations in adult acute myeloid leukaemia. British Journal of Haematology, 113, 983-988.
4. Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Peake, I.R. & Reilly, J.T. (2003) Mutational analysis of c-FMS in acute myeloid leukaemia. British Journal of Haematology, 123, 749-750.
5. Adya, N., Stacy, T., Speck, N.A. & Liu, P. (1998) The leukemic protein core binding factor β (CBFβ)-smooth-muscle myosin heavy chain sequesters CBFa2 into cytoskeletal filaments and aggregates. Molecular and Cellular Biology, 18, 7432-7443.
6. Alland, L., Muhle, R., Hou, H., Potes, J., Chin, L., Schreiber-Agus, N. & De Pinho, R.A. (1997) Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature, 387, 49-55.
7. Amann, J.M., Nip, J., Strom, D.K., Lutterbach, B., Harada, H., Lenny, N., Downing, J.R., Meyers, S. & Hiebert, S.W. (2001) ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Molecular and Cellular Biology, 21, 6470-6483.
8. Arthur, D.C. & Bloomfield, C.D. (1983) Partial deletion of the long arm of chromosome 16 and bone marrow eosinophilia in acute nonlymphocytic leukemia: a new association. Blood, 61, 994-998.
9. Asou, N., Sanada, I., Tanaka, K., Hidaka, M., Suzushima, H., Matsuzaki, H., Kawano, F. & Takatsuki, K. (1992) Inversion of chromosome 16 and bone marrow eosinophilia in a myelomonocytic transformation of chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 61, 197-200.
10. Aventin, A., la Starza, R., Nomdedeu, J., Brunei, S., Sierra, J. & Mecucci, C. (2000) Typical CBFbeta/MYH11 fusion due to insertion of the 3′-MYH11 gene into 16q22 in acule monocytic leukemia with normal chromosomes 16 and trisomies 8 and 22. Cancer Genetics and Cytogenetics, 123, 137-139.
11. Basecke, J., Cepek, L., Mannhalter, C., Krauler, J., Hildenhagen, S., Brittinger, G., Trumper, L. & Griesinger, F. (2002) Transcription of AML1/ETO in bone marrow and cord blood of individuals without acule myelogenous leukemia. Blood, 100, 2267-2268.
12. Beaupre, D.M. & Kurzrock, R (1999) RAS and leukemia: from basic mechanisms to gene-directed therapy. Journal of Clinical Oncology, 17, 1071-1079.
13. Beghini, A., Cairoli, R., Morra, E. & Larizza, L. (1998) In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells, Molecules, and Diseases, 24, 262-270.
14. Beghini, A., Peterlongo, P., Ripamonti, C.B., Larizza, L., Cairoli, R., Morra, E. & Mecucci, C. (2000a) c-kit mutations in core binding factor leukemias. Blood, 95, 726-727.
15. Beghini, A., Ripamonti, C.B., Castorina, P., Pezzetti, L., Doneda, L., Cairoli, R., Morra, E. & Larizza, L. (2000b) Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia wilh mast cell involvement Cancer Genetics and Cytogenetics, 119, 26-31.
16. Beghini, A., Magnani, I., Ripamonti, C.B. & Larizza, L. (2002) Amplification of a novel c-kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-kit mutant model for acule myeloid leukemia. Haematology Journal, 3, 57-63.
17. Berger, R. & Coniat, M.B. (2000) Uneven frequencies of secondary chromosomal abnormalities in acute myeloid leukemias with t(8;21); t(15;17) and inv(16). Cancer Genetics and Cytogenetics, 117, 159-162.
18. Bloomfield, C.D., Lawrence, D., Byrd, J.C., Carroll, A., Pattenati, M.J., Tantravahi, R., Patil, S.R., Davey, F.R., Berg, D.T., Schiffer, C.A., Arthur, D.C. & Mayer, R.J. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype myeloid leukemia varies by cytogenetic subtype. Cancer Research, 58, 4173-4179.
19. Böll, I., Schoch, C., Haferlach, T., Hiddemann, W. & Schnittger, S. (2002) Not only c-KIT exon 8-, but also NRAS- and FLT3D835-mutations are frequent molecular alterations in patients with acute myeloid leukemia M4eo and inv(16). Blood, 100, 746a.
20. Broudy, V.C., Lin, N.L. & Sabath, D.F. (2001) The fifth immunoglobulin-like domain of the Kit receptor is required for proteolytic cleavage from the cell surface. Cytokine, 15, 188-195.
21. Brown, P. & Small, D. (2004) FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancers. European Journal of cancer, 40, 707-721.
22. Buchdunger, E., Cioffi, C.L., Law, N., Stover, D., Ohno-Jones, S., Druker, B.J. & Lynden, N.B. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by the c-kit and platelet-derived growth factor receptors. Journal of Pharmacology and Experimental Therapy, 295, 139-145.
23. Bullinger, L., Dohner, K., Bair, E., Frohling, S., Schlenk, R.F., Tibshirani, R., Dohmer, H. & Pollack, J.R. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult myeloid leukemia. New England Journal of Medicine, 350, 1605-1616.
24. Burnett, A.K., Wheatley, K., Goldstone, A.H., Stevens, R.F., Hann, I.M., Rees, J.H. & Harrison, G. (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology, 118, 385-400.
25. Byrd, J.C., Mrozek, K., Dodge, R.K., Carroll, A.J., Edwards, C.G., Arthur, D.C., Pettenati, M.J., Patil, S.R., Rao, K.W., Watson, M.S., Koduru, P.R., Moore, J.O., Stone, R.M., Mayer, R.J., Feldman, E.J., Davey, F.R., Schiffer, C.A., Larson, R.A. & Bloomfield, C.D. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de nova acute myeloid leukemia: results from CALGB 8461. Blood, 100, 4325-4336.
26. Cameron, S., Taylor, D.S., TePas, E.G., Speck, N.A. & Mathey-Prevot, B: (1994) Identification of a crucial regulatory site in the human interleukin-3 promoter by in vivo footprinting. Blood, 83, 2851-2859.
27. Cao, W., Adya, N., Britos-Bray, M., Liu, P.P. & Friedman, A.D. (1998) The core binding fcator (CBF) α interaction domain and the smooth muscle myosin heavy chain (SMMHC) segment of CBFβ-SMMHC are both required to slow cell proliferation. Journal of Biological Chemistry, 273, 31534-31540.
28. Care, R.S., Valk, P.J.M., Goodeve, A.C., Abu-Duhier, F.M., Geertsma-Kleinekoort, W.M.C., Wilson, G.A., Gari, M.A., Peake, I.R. Löwenburg, B. & Reilly, J.T. (2003) Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. British Journal of Haematology, 121, 773-777.
29. Castilla, L.H., Wijmenga, C., Wang, Q., Stacy, T., Speck, N.A., Eckhaus, M., Marin-Padilla, M., Collins, F.S., Wynshaw-Boris, A. & Liu, P.P. (1996) Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knock-in leukemia gene CBFβ-MYH11. Cell, 87, 687-696.
30. Castilla, L.H., Garrett, L., Adya, N., Orlic, D., Dutra, A., Anderson, S., Owens, J., Eckhaus, M., Bodline, D. & Liu, P.P. (1999) The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nature Genetics, 23, 144-146.
31. Castilla, L.H., Perrat, P., Martinez, N.J., Landrette, S.F., Keys, R., Oikemus, S., Flanegan, J., Heilman, S., Garrett, L., Dutra, A., Anderson, S., Pihan, G.A., Wolff, L. & Liu, P.P. (2004) Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 101, 4924-4929.
32. Chan, I.T., Kutok, J.L., Williams, I.R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D.A., Jacks, T. & Gilliland, D.G. (2004) Conditional expression of oncogenic K-ras from its endogenous promotor induces a myeloproliferative disease. Journal of Clinical Investigation, 113, 528-538.
33. de la Chapelle, A. & Lahtinen, R. (1983) Chromosome 16 and bone-marrow eosinophilia. New England Journal of Medicine, 309, 1394.
34. Chen, C.-Y., Tsay, W., Tang, J.-L., Shen, H.-L., Lin, S.-W., Huang, S,-Y., Yao, M., Chen, Y.-C., Shen, M.-C., Wang, C.-H. & Tien, H.-F. (2003) SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes, Chromosomes & Cancer, 37, 300-305.
35. Chim, C.S., Wong, A.S. & Kwong, Y.L. (2004) Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute myeloid leukaemia. Annals of Hematology, 83, 527-532.
36. Cilloni, D., Carturan, S., Gottardi, E., Messa, P., Messa, E., Fava, M, Diverio, D., Guerrasio, A., Lo-Coco, F. & Saglio, G. (2003) Down-modulation of the C/EBPα transcription factor in core binding factor acute myeloid leukemias. Blood, 102, 2705-2706.
37. Claxton, D.F., Liu, P., Hsu, H.B., Marlton, P., Hester, J., Collins, F., Deisseroth, A.B., Rowley, J.D. & Siciliano, M.J. (1994) Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood, 83, 1750-1756.
38. Colovic, M., Jankovic, G., Bila, J., Djordevic, V. & Wiermk, P.H. (1998) Inversion of chromosome 16 in accelerated phase of chronic myeloid leukaemia: report of a case and review of literature. Medical Oncology, 15, 199-201
39. Costello, R., Sainty, D., Lecine, P., Cusenier, A., Mozziconacci, M.J., Arnoulet, C., Maraninchi, D., Gastaut, J.A., Imbert, J., Lafage-Pochitaloff, M. & Gabert, J. (1997a) Detection of CBFβ-MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics. Leukemia, 11, 644-650.
40. Costello, R., Sainty, D., Blaise, D., Gastaut, J.A., Gabert, J., Poirel, H., Buzyn-Veil, A. & Macintyre, E. (1997b) Prognosis value of residual disease monitoring by polymerase chain reaction in patients with CBFbeta/MYH11-positive acute myeloblastic leukemia. Blood, 89, 2222-2223.
41. Cuenco, G.M. & Ren, R. (2001) Cooperation of BCR-ABL and AML!/MDS/EVI1 in blocking myeloid differentiation and rapid induction of an acute myeloid leukemia. Oncogene, 20, 8236-8248.
42. Dauwerse, H.G., Smit, E.M.E., Giles, R.H., Slater, R., Breuning, M.H., Hagemeijer, A. & Van der Reijden, B.A. (1999). Two-color FISH detection of the inv(16) in interphase nuclei of patients with acute myeloid leukemia. British Journal of Haematology, 106, 111-114.
43. Delaunay, J., Vey, N., Leblanc, T., Fenaux, P., Rigal-Huguet, F., Witz, F., Lamy, T., Auvrignon, A., Blaise, D., Pigneux, A., Mugneret, F., Bastard, C., Dastugue, N., van der Akker, J., Fière, D., Reiffers, J., Castaigne, S., Leverger, G., Harousseau, J-L. & Dombret, H. (2003) Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood, 102, 462-469.
44. Dissing, M., Lebeau, M.M. & Pedersen-Bjergaard, J. (1998) Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukaemia: rare events related to DNA-topoisomerase II inhibitors? Journal of Clinical Oncology, 16, 1890-1896.
45. Druker, B.J. & Lydon, N.B. (2000) Lessons learned from the development of an abl tyrosine inhibitor for chronic myelogenous leukemia. Journal of Clinical Investigation, 105, 3-7.
46. Durst, K.L., Lutterbach, B., Kummalue, T., Friedman, A.D. & Hiebert, S.W. (2003) The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Molecular and Cellular Biology, 23, 607-619.
47. Enright, H., Weisdorf, D., Peterson, L., Rydell, R.E., Kaplan, M.E. & Arthur, D.C. (1992) Inversion of chromosome 16 and dysplastic eosinophils in accelerated phase of chronic myeloid leukaemia. Leukaemia, 6, 381-384.
48. Evers, J.P., Bagg, A., Himoe, E., Zwiebel, J.A. & Jacobson, R.J. (1992) Temporal association of marrow eosinophilia with inversion of chromosome 16 in recurrent blast crisis of chronic myelogenous leukemia. Cancer Genetics and Cytogenetics, 62, 134-139.
49. Fenrick, R., Amann, J.M., Lutterbach, B., Wang, L., Westendorf, J.J., Downing, J.R. & Hiebert, S.W. (1999) Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Molecular and Cellular Biology, 19, 6566-6574.
50. Ferro, M.T., Steegman, J.L., Escribano, L., Heiurichs, B., Parada, L., Garcia-Sagredo, J.M., Resino, M., Cabello, P. & San Roman, C. (1992) Ph-positive chronic myeloid leukaemia with t(8;21)(q22;q22) in blastic crisis. Cancer Genetics and Cytogenetics, 58, 96-99.
51. Fourth International Workshop on Chromosomes in Leukemia: a prospective study of acute nonlymphocytic leukemia (1984). Cancer Genetics and Cytogenetics, 11, 249-360.
52. Frohling, S., Schlenk, R.F., Breitruck, I., Brenner, A., Kreitmeier, S., Tobis, K. Dohner, H. & Dohner, K. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study GroupUlm. Blood, 100, 4372-4380.
53. Gad, S.G., Callen, D.F., Kuss, B., Downing, J.R., Behm, F., Head, D., Ribeiro, R.C. & Raimondi, S.C. (1993) Identification of an inversion 16 coexisting with an isochromosome 22q by in situ hybridization in a case of childhood AML M4e. Leukemia, 7, 1658-1662.
54. Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., Vandenberghe, E., Peake, I. & Reilly, J. (1999) c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. British Journal of Haematology, 105, 894-900.
55. Gilliland, D.G. (2001) Hematologic malignancies. Current Opinions in Haematology, 8, 189-191.
56. Godon, C., Proffitt, I., Dastugue, N., Lafage-Pochitaloff, M., Mozziconacci, M-J., Talmant, P., Hackbarth, M., Bataille, R. & Avet-Loiseau, H. (2002) Large deletions 5′ to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia. Leukemia, 16, 1752-1754.
57. Goemans, B.F., Zwaan, CM., Miller, M., Zimmermann, M., Hahlen, K., Reinhardt, D., Creutzig, V., Kaspers, G.J.L. & Heinrich, M.C. (2003) Incidence and prognostic significance of c-kit exon 8 and 17 mutations in pediatric acute myeloid leukemia (AML). Blood, 102, 198b.
58. Golub, T.R., Barker, G.F., Lovett, M. & Gilliland, D.G. (1994) Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell, 77, 307-316.
59. Golub, T.R., Barker, G.F., Bohlander, S.K., Hiebert, S.W., Ward, D.C., Bray-Ward, P., Morgan, E., Raimondi, S.C., Rowley, J.D. & Gilliland, D.G. (1995) Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 92, 4917-4921.
60. Grardel, N., Roumier, C., Soenen, V., Lai, J.L., Plantier, I., Gheveart, C., Cosson, A., Fenaux, P. & Preudhomme, C. (2002) Acute myeloblastic leukemia (AML) with inv(16)(p13;q22) and the rare I type CBFβ-MYH11 transcript: report of two new cases. Leukemia, 16, 150-156.
61. Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood, 92, 2322-2333.
62. Grisolano, J.L., O'Neal, J., Cain, J. & Tomasson, M.H. (2003) An activated receptor tyrosine kinase, TEL/PDGFβR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America, 100, 9506-9511.
63. Haferlach, T., Winkemann, M., Loffler, H., Schoch, R., Gassmann, W., Fonatsch, C., Schoch, C., Poetsch, M., Weber-Matthiesen, K. & Schlegelberger, B. (1996) The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4eo) and carry the pericentric inversion 16: a combination of May-Grunwald-Giemsa staining and fluorescence in situ hydridization. Blood, 87, 2459-2463.
64. Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H. & Naoe, T. (2000) Tandem-duplicated flt3 constitutively activates STAT5 and MAP kinase and induces autonomous cell growth in I1-3-dependent cell lines. Oncogene, 19, 624-631.
65. He, L.Z., Guidez, F., Tribioli, C, Peruzzi, D., Ruthardt, M., Zelent, A. & Pandolfi, P.P. (1998) Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nature Genetics, 18, 126-135.
66. Hébert, J., Cayuela, JM., Daniel, MT., Berger, R. & Sigaux, F. (1994) Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal eosinophils by nested polymerase chain reaction with allele specific amplification. Blood, 84, 2291-2296.
67. Heim, S., Christensen, B.E., Fioretos, T., Sorensen, A.G., Pedersen, N.T. (1992) Acute myelomonocytic leukemia with inv(16)(p13;q22) complicating Philadelphia chromosome positive chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 59, 35-38.
68. Heinzel, T., Lavinsky, R.M., Müllen, T-M., Soderstrom, M., Laherty, C.D., Torchia, J., Yang, W.M., Brard, G., Ngo, S.D., Davie, J.R., Seto, E., Eisenman, R.N., Rose, D.W., Glass, CK. & Rosenfeld, M.G.. (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature, 387, 43-48.
69. Higuchi, M., O'Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E-J. & Downing, J.R. (2002) Expression of a conditional AML1-ETO oncogene by-passes embryonic lethality and establishes a murine model of t(8;21) acute myeloid leukaemia. Cancer Cells, 1; 63-74.
70. Hiwatari, M., Taki, T., Tsuchida, M., Hanada, R., Hongo, T., Sako, M. & Hayashi, Y. (2003) Mutation of c-KIT and platelet-derived growth factor receptor (PDGFR) α genes in childhood acute myeloid leukemia and leukemic cell lines. Blood, 102, 865a.
71. Huang, G., Shigesada, K., Ito, K., Wee, H.J., Yokomizo, T. & Ito, Y. (2001) Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO Journal, 20, 723-733.
72. Huang, G., Shigesada, K., Wee, H. J., Liu, P.P., Osata, M. & Ito, Y. (2004) Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood, 103, 3200-3207.
73. Huntly, B.J., Bench, A. & Green, A.R. (2003) Double jeopardy from a single translocation: deletions of the derivitive chromosome 9 in chronic myeloid leukemia. Blood, 102, 1160-1168.
74. Johansson, B., Mertens, F. & Mitelman, F. (1994) Secondary chromosomal abnormalities in acute leukemias. Leukemia, 8, 953-962.
75. Jonkers, J. & Berns, A. (1996) Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochimica et Biophysica Acta, 1287, 29-57.
76. Johan, M.F., Bowen, D.T., Frew, M.E., Goodeve, A.C., Wilson, G.A., Peake, I.R. & Reilly, J.T. (2004a) Mutations in PTPN11 are un-common in adult myelodysplastic syndromes and acute myeloid leukaemia. British Journal of Haematology, 124, 843.
77. Johan, M.F., Goodeve, A.C. & Reilly, I.T (2004b) Activating loop mutations in the PDGFRα and β genes are rare in core binding factor (CBF) acute myeloid leukaemia (AML). British Journal of Haematology, 127, 123-124.
78. Kamachi, Y., Ogawa, E., Asano, M., Ishida, S., Murakami, Y., Satake, M., Ito, Y. & Shigesada, K. (1990) Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. Journal of Virology, 64, 4808-4819.
79. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. & Gilliland, D.G. (2002a) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disorders in a murine bone marrow transplant model. Blood, 99, 310-318.
80. Kelly, L.M., Kutok, J.L., Williams, I.R., Boulton, C.L., Amoral, S.M., Curley, D.P., Ley, T.J. & Gilliland, D.G. (2002b) PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 99, 8283-8288.
81. Kiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H. & Naoe, T (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of product. Leukemia, 12, 1333-1337.
82. Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., Akiyama, H., Saito, K., Oh, H., Motoji, T., Omoto, E., Saito, H., Ohno, R. & Ueda, R. (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood, 93, 3074-3080.
83. Klisovic, M.I., Maghraby, E.A., Parthun, M.R., Guimond, M., Sklenar, A.R., Whitman, S.P. Chan, K.K., Murphy, T., Anon, J., Archer, K.J., Rush, L.J., Plass, C., Grever, M.R., Byrd, J.C. & Marcucci, G. (2003) Depsipeptide (FR 901228) promotes histone acetyation, gene transcription, apoptosis and its activity is enhanced by DNA methyl-transferase inhibitors in AML1/ETO positive leukemic cells. Leukemia, 17, 350-358.
84. Kogan, S.C., Lagasse, E., Atwater, S., Bae, S.C., Weissman, I., Ito, Y. & Bishop, J.M. (1998) The PEBP2β11 fusion created by inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia. Proceedings of the National Academy of Sciences of the United States of America, 95, 11863-11868.
85. Kojima, K, Yasukawa, M., Ishimaru, F., Dansako, H., Matsuo, Y., Kimura, Y., Nawa, Y., Hara, M. & Harada, M. (1999) Additional translocation (8;21)(q22;q22) in a patient with Philadelphia-positive chronic myeloid leukaemia in blastic phase. British Journal of Haematology, 106, 720-722.
86. Kolomietz, E., Al-Maghrabi, J., Brennan, S., Karaskova, J., Minkin, S., Lipton, J. & Squire, J.A. (2001) Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive sub-microscopic deletions and may lead to altered prognosis. Blood, 97, 3581-3588.
87. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., Sato, M., Okamoto, R., Kitamura, Y., Yoshiki, S. & Kishimoto, T. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell, 89, 755-764.
88. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy analysis of 854 patients from the United Kingdom Research Council AML 10 and 12 trials. Blood, 98, 1752-1759.
89. Kundu, M., Chen, A., Anderson, S., Kirby, M., Xu, L., Castilla, L.H., Bodine, D. & Liu, P.P. (2002) Role of Cbfb in hematopoiesis and perturbations resulting from expression of the leukemogenic fusion gene Cbfb-MYH11. Blood, 100, 2449-2456.
90. Kuss, B., Deeley, R.G., Cole, S.P., Willman, C.L., Kopecky, K.J., Wolman, S.R., Eyre, H.J. & Callen, D.F. (1996) The biological significance of the multidrug resistence gene MRP in inversion 16 leukemias. Leukemia and Lymphoma, 20, 357-364.
91. Kuss, B.J., O'Neill, G.M., Eyre, H., Doggett, N.A., Callen, D.F. & Davey, R.A. (1998) ARA, a novel ABC transporter, is located at 16p13·1, is deleted in inv(16) leukemias, and is shown to be expressed in primitive hematopoietic precursors. Genomics, 51, 455-458.
92. Lacayo, N., Kinnunen, P., Raimondi, S.C., Yu, R., Wahab, R., Stuber, C., Douglas, L., Chang, M., Willman, C.L., Ravindranath, Y., Weinstein, H., Becton, D., Behm, P., Tibshirani, R., Sikie, B.I. & Dahl, G.V. (2003) Gene expression profiling (GEP) in de novo pediaric acute myeloid leukemia (AML) patients reveals a robust expression signature that correlates with inv(16) and t(16;16). Blood, 102, 365a
93. Lancet, J.E. & Karp, J.E. (2003) Farnesyl transferase inhibitors in myeloid malignancies. Blood Reviews, 17, 123-129.
94. Landrette, S., Perrat, P., Hensen, K., Ven, V. & de Castilla, L. (2002) Oncogenes PLAG1 and PLAG2 synergize with CBFβ-MYH11 in AML. Blood, 100, 85a.
95. Lane, A.A. & Ley, T.J. (2004) Neutrophil ekstase cleaves PML-RARα and is important for the development of acute promyelocytic leukemia in mice. Cell, 115, 305-318.
96. Langabeer, S.E., Grimwade, D., Walker, H., Rogers, J.R., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (1998) A study to determine whether trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements of PML/RARalpha, AML1/ETO and CBFβ/MYH11 respectively in acute myeloid leukemia. British Journal of Haematology, 101, 338-340.
97. Larson, R.A., Williams, S.F., Beau, MM.., Bitter, M.A., Vardiman, J.W. & Rowley, J.D. (1986) Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favourable prognosis. Blood, 68, 1242-1249.
98. Lasa, A., Carnicer, M.J., Aventin, A., Estivill, C., Brunet, S., Sierra, J. & Nomdedeu, J.F. (2004) MEIS I expression is downregulated through promoter hypermethylation in AML-ETO acute myeloid leukemia. Leukemia, 18, 1231-1237.
99. Le Beau, M.M., Larson, R.A., Bitter, M.A., Vardiman, J.W., Golomb, H.M. & Rowley, J.D. (1983) Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association. New England of Journal of Medicine, 309, 630-636.
100. Libura, M., Asnafi, V., Tu, A., Delabesse, E., Tigaud, I., Cymbalista, F., Bennaceur-Griscelli, A., Villarese, P., Solbu, G., Hagemeijer, A., Beldjord, K., Hermine, O. & Macintyre, E. (2003) FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood, 102, 2198-2204.
101. Liu, P., Tarle, S.A., Hajra, A., Claxton, D.F., Marlton, P., Freedman, M., Siciliano, M.J. & Collins, F.S. (1993) Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science, 261, 1041-1044.
102. Liu, P.P., Hajra, A., Wijmenga, C. & Collins, F.S. (1995) Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood, 85, 2289-2302.
103. Look, A.T. (1997) Oncogenic transcription factors in the human acute leukemias. Science, 278, 1059-1064.
104. Lukasik, S.M., Zhang, L., Corpora, T., Tomanicek, S., Li, Y., Kundu, M., Hartman, K., Liu, P. P., Laue, T.M., Biltonen, R.L., Speck, N.A. & Bushweller, J.H. (2002) Altered affinity of CBFβ-SMMHC for Runx1 explains its role in leukemogenesis. Nature Structural Biology, 9, 674-679.
105. Lutterbach, B., Hou, Y., Durst, K.L. & Hiebert, S.W. (1999) The inv(16) encodes an acute myeloid leukemia 1 transcription corepressor. Proceedings of the National Academy of Sciences of the United States of America, 96, 12822-12827.
106. McHale, C.M., Wiernels, J.L., Zhang, L., Ma, X., Buffler, P.A., Feusner, J., Matthay, K., Dahl, G. & Smith, M.T. (2003) Prenatal origin of childhood acute myeloid leukemias harbouring chromosomal rearrangements t(15;17) and inv(16). Blood, 101, 4640-4641.
107. MacKenzie, K.L., Dolnikov, A., Millington, M., Shounan, Y. & Symonds, G. (1999) Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood, 93, 2043-2056.
108. Marlton, P., Claxton, D.F., Liu, P., Estey, E.H., Beran, M., le Beau, M., Testa, J.R., Collins, F.S., Rowley, J.D. & Siciliano, M.J. (1995) Molecular characterization of I6p deletions associated with inversion 16 defines the critical fusion for leukemogenesis. Blood, 85, 772-779.
109. Martinet, D., Muhlematter, D., Leeman, M., Parlier, V., Hess, U., Gmur, J. & Jutterand, M. (1997) Detection of 16p deletions by FISH in patients with inv(16) or t(16;16) and acute myeloid leukemia (AML). Leukemia, 11, 964-970.
110. Martinez-Climent, J.A., Comes, A.M., Vizcarra, E., Reshmi, S., Benet, I., Marugan, I., Tormo, M., Terol, M.J., Solano, C., Arbona, C., Prosper, F., Barragan, E., Bolufer, P., Rowley, J.D. & Garcia-Conde, J. (1999) Variant three-way translocation of inversion 16 in AML-M4Eo confirmed by fluorescence in situ hybridization analysis. Cancer Genetics and Cytogenetics, 110, 111-114.
111. Matsuno, N., Osato, M., Yamashita, N., Yanagida, M., Nanri, T., Fukushima, T., Motoji, T., Kusumoto, S., Towatari, M., Suzuki, R., Naoe, T., Nishii, K., Shigesada, K., Ohno, R., Mitsuya, H., Ito, Y. & Asou, N. (2003) Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the MO subtype. Leukemia, 17, 2492-2499.
112. Melnick, A. & Licht, J.D. (2000) Deconstructing a disease: RARα, its fusion partners, and their roles in the pathoigenesis of acute promyelocytic leukemia. Blood, 93, 3167-3215.
113. Meyers, S., Downing, J.R. & Hiebert, S.W. (1993) Identification of AML1 and the (8;21) translocation protein AML1-ETO as sequence specific DNA binding proteins: the runt domain is required for DNA binding and protein-protein interactions. Molecular and Cellular Biology, 13, 6336-6345.
114. Meyers, S., Lenny, N. & Hiebert, S.W. (1995) The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Molecular and Cellular Biology, 15, 1974-1982.
115. Michaud, J., Wu, F., Osata, M., Cottles, G.M., Yanagida, M., Asou, N., Shigesada, K., Ito, Y., Benson, K.F., Raskind, W.H., Rossier, C., Antonarakis, S.E., Israels, S., McNicol, A., Weiss, H., Horwitz, M. & Scott, H.S. (2002) In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with pre-disposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood, 99, 1364-1372.
116. Miller, J.D., Stacy, T., Piu, P.P. & Speck, N.A. (2001) Core binding factor β (CBFβ), but not CBFβ-smooth muscle myosin heavy chain, rescues definitive hematopoiesis in CBFβ-deficient embyronic stem cells. Blood, 97, 2248-2256.
117. Mitani, K., Ogawa, S., Tanaka, T., Miyoshi, H., Kurokawa, M., Mano, H., Yazaki, Y., Ohki, M. & Hirai, H. (1994) Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO Journal, 13, 504-510.
118. Miyamoto, T., Nagafugi, K., Akashi, K., Harada, M., Kyo, T., Akashi, T., Takenaka, K., Mizuno, S., Gondo, H., Okamura, T., Dohy, H. & Niho, Y. (1996) Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood, 87, 4789-4796.
119. Miyamoto, T., Weissman, I.L. & Akashi, K. (2000) AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proceedings of the National Academy of Sciences of the United States of America, 97, 7521-7526.
120. Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y. & Ohki, M. (1991) The t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia clustered within a limited region of a novel gene AML1. Proceedings of the National Academy of Sciences of the United States of America, 88, 10431-104434.
121. Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Muller, C, Gruning, W., Kratz-Albers, K., Serve, S., Steur, C., Buchner, T., Kienast, J., Kanakura, Y., Berdel, W.E. & Serve, H. (2000) FLT3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT pathways. Blood, 96, 3907-3914.
122. Mohamed, A.N., Pemberton, P., Zonder, J. & Schiffer, C.A. (2003) The effect of imatinib mesylate on patients with Philadelphia chromosomal aberrations. Clinical Cancer Research, 9, 1333-1337.
123. Mori, H., Colman, S.M., Xiao, Z., Ford, A.M., Healy, L.E., Donaldson, C., Hows, J.M., Navarrete, C. & Greaves, M. (2002) Chromosomal translocations and covert leukemic clones are generated during normal fetal development. Proceedings of the National Academy of Sciences of the United States of America, 99, 8242-8247.
124. Mueller, B.U., Pabst, T., Osata, M., Asou, N., Johansen, L.M., Minden, M.D., Behre, G., Hiddemann, W., Ito, Y. & Tenen, D.G. (2002) Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood, 100, 998-1007.
125. Mulloy, J.C., Cammenga, J., MacKenzie, K.L., Berguido, FG.J., Moore, M.A. & Nimer, S.D. (2002) The AML1-ETO fusion gene promotes the expansion of human haematopoietic stem cells. Blood, 99, 15-23.
126. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T. & Misawa, S. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 1911-1918.
127. Niki, M., Okada, H., Takano, H., Kuno, J., Tani, K., Hibino, H., Asano, S., Ito, Y., Satake, M. & Noda, T. (1997) Hematopoiesis in the fetal liver is impaired by the targeted mutagenesis of the gene encoding a non-DNA binding subunit of the transcription factor, PEBP2/CBF. Proceedings of the National Academy of Sciences of the United States of America, 94, 5697-5702.
128. Nomdedeu, J.F., Brunet, S., Colomer, D., Estivill, C., Llorente, J., Carnicer, M.J., Esteve, J. & Sierra, J. (2001) D835 mutations are commonly associated with other molecular lesions in adult AML. Blood, 98, 579a.
129. Nuchprayoon, I., Meyers, S., Scott, L.M., Suzow, J., Hiebert, S. & Friedman, A.D. (1994) PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2β/CBFβ proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Molecular and Cellular Biology, 14, 5558-5568.
130. Nucifora, G., Larson, R.A. & Rowley, J.D. (1993) Peristence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood, 82, 712-715.
131. Ogawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M., Shigesada, K. & Ito, Y. (1993a) PEBP2/PEA2 represents a family of transcription factors homologous to the products of of the Drosophila runt gene and the human AML1 gene. Proceedings of the National Academy of Sciences of the United States of America, 90, 6859-6863.
132. Ogawa, E., Inuzuka, M., Maruyama, M., Satake, M., Naito-Fujimoto, M., Ito, Y. & Shigesada, K. (1993b) Molecular cloning and characterization of PEBP2 β, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEPB2 a. Virology, 194, 314-331.
133. Okuda, T., van Deursen, J., Hiebert, S.W., Grosveld, G. & Downing, J.R. (1996) AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell, 84, 321-330.
134. O'Reilly, J., Chipper, L., Springall, F. & Herrmann, R. (2000) A unique structural abnormality of chromosome 16 resulting in a CBF beta-MYh11 fusion transcript with acute myeloid leukemia, FAB M4. Cancer Genetics and Cytogenetics, 121, 52-55.
135. Pabst, T., Mueller, B.U., Zhang, P., Radomska, H.S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W. & Tenen, D.G. (2001a) Dominant-negative mutations of CEBPA encoding CCAAT/enhancing binding protein-α (CEBPα) in acute myeloid leukaemia. Nature Genetics, 27, 263-270.
136. Pabst, T., Mueller, B.U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.E. & Tenen, D.G. (2001b) AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukaemia. Nature Medicine, 7, 444-451.
137. Poirel, H., Radford-Weiss, I., Rack, K., Troussard, X., Veil, A., Valensi, R, Picard, F., Guesnu, M., Leboeuf, D., Melle, J., Dreyfus, F., Flandrin, G. & Macintyre, E. (1995). Detection of the chromosome 16 CBFb-MYH11 fusion transcript in myelomonocytic leukemias. Blood, 85, 1313-1322.
138. Preudhomme, C, Warot-Loze, D., Roumier, C., Grardel-Duflos, N., Garand, R., Lai, J.L., Dastugue, N., Macintyre, E., Denis, C., Bauters, F., Kerchaert, J.P., Cosson, A. & Fenaux, P. (2000) High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 βB gene in MO acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood, 96, 2862-2869.
139. Preudhomme, C., Sagot, C., Boissel, N., Cayuela, J.M., Tigaud, I., de Botton, S., Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., Fenaux, P., Dombret, H. (2002) Favourable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukaemia: a study from the Acute Leukemia French Association (ALFA). Blood, 100, 2717-27723.
140. Ramsey, H., Zhang, Do-E., Richkind, K., Burcoglu-O'Ral, A. & Hromas, R. (2003) Fusion of AML1/Runx1 to Copine VIII, a novel member of the copine family, in an aggressive acute myelogenous leukemia with t(12;21) translocation. Leukemia, 17, 1665-1685.
141. Ramsey, H., Christopherson, K. & Hromas, R. (2004) Forced expression of AML1-AMP19, a fusion transcript generated from a radiation-associated t(19;21) leukemia, blocks myeloid differentiation. Leukaemia Research, 28, 863-868.
142. Razzouk, B.I., Raimondi, S.C., D.K., Pritchard, M., Behm, F.G., Tong, X., Sandlund, J.T., Rubnitz, J.E., Pui, Srivastava, C.H. & Ribeiro, R.C. (2001) Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia, 15, 1326-1330.
143. Redondo, J.M., Pfohl, J.L., Hernandez-Munain, C., Wang, S., Speck, N.A. & Krangel, M.S. (1992) Indistinguishable nuclear factor binding to functional core sites of the T-cell receptor δ and murine leukemia virus enhancers. Molecular and Cellular Biology, 12, 4817-4823.
144. Reilly, J.T. (2002) Class III receptor tyrosine kinases: role in leukaemogenesis. British Journal of Haematology, 116, 744-757.
145. Reuter, C.W., Morgan, M.A. & Bergmann, L. (2000) Targeting the Ras signalling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood, 96, 1655-1669.
146. Rhoades, K.L., Hetherington, C.J., Rowley, J.D., Hiebert, S.W., Nucifora, G., Tenen, D.G., D.G. & Zhang, D.E. (1996) Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis. Proceedings for the National Academy of Sciences of the United States of America, 93, 11895-11900.
147. Rhoades, K.L., Hetherington, C.J., Harakawa, N., Yergeau, D.A., Zhou, L., Liu, L.Q., Little, M.T., Tenen, D.G. & Zhang, D.E. (2000). Analysis of the role of AML-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood, 96, 2108-2115.
148. Schmitz, N., Gödde-Salz, E., Gassmann, W. & Löffler, H. (1984) Acute myelomonocytic leukemia with involvement of eosinophils and inversion of chromosome 16. Blut, 48, 263-267.
149. Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Löffler, H., Sauerland, C.M., Serve, H., Buchner, T., haferlach, T. & Hiddemann, W. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AML CG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 59-66.
150. Scolnik, M.P., Palacios, M.F., Acevedo, S.H., Castuma, M.V., Larripa, I.B., Palumbo, A., Moiraghi, E.B., Sasot, A.M. & Huberman, A.B. (1998) Promyelocytic blast crisis of chronic myelogenous leukaemia with translocations (9;22) and (15;17). Leukemia and Lymphoma, 31, 231-236.
151. Shurtleff, S.A., Meyers, S., Hiebert, S.W., Raimondi, S.C., Head, D.R., Willman, C.L., Wolman, S., Slovak, M.L., Carroll, A.J. & Behm, F. (1995) Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13;q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia. Blood, 85, 3695-3703.
152. Springall, F.H., Lukeis, R.L., Tyrrell, V., Joshua, D.E. & Hand, H.J. (1998) Identification of a novel CBFβ-MYH11 fusion transcript in a patient with AML and inversion of chromosome 16. Leukemia, 12, 2034-2039.
153. Stirewalt, D.L., Kopecky, K.J., Meshinchi, S., Appelbaum, F.R., Slovak, M.L., Willman, C.L. & Radich, J.P. (2001) FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukaemia. Blood, 97, 3589-3595.
154. Stocking, C., Schwieger, M., Forster, M., Horak, I. & Löhler, J. (2002) Mouse models for AML1-ETO transformation and identification of cooperating mutations. Blood, 100, 33a.
155. Takahashi, A., Satake, M., Yamaguchi-Iwai, Y., Bae, S.C., Lu, J., Maruyama, M., Zhang, Y.W., Oka, H., Arai, N., Arai, K. & Ito, Y. (1995) Positive and negative regulation of granulocytic-macrophage colony-stimulating factor promoter activity by AML-1 related transcription factor, PEBP2. Blood, 86, 607-616.
156. Tantravahi, R., Schwenn, M., Henkle, C., Nell, M., Leavitt, P.R., Griffin, J.D. & Weinstein, H.J. (1984) A pericentric inversion of chromosome 16 is associated with dysplastic marrow eosinophils in acute myelomonocytic leukemia. Blood, 63, 800-802.
157. Tartaglia, M., Niemeyer, C.M., Fragale, A., Song, X., Buechner, J., Jung, A., Hahlen, K., Hasle, H., Licht, J.D. & Gelb, B.D. (2003) Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics, 63, 423-426.
158. Testa, J.R., Hogge, D.E., Misawa, S. & Zandparsa, N. (1984) Chromosome 16 rearrangements in acute myelomonocytic leukemia with abnormal eosinophils. New England Journal of Medicine, 310, 468-469.
159. Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 4326-4335.
160. Tobal, K., Johnson, P.R., Saunders, M.J., Harrison, C.J. & Liu Yin, J.A. (1995) Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. British Journal of Haematology, 91, 104-110.
161. Trnkova, Z., Pekova, S., Bedrlikova, R., Zakova, D., Zemanova, Z., Polak, J., Michalova, K., Cermak, J. & Schwarz, J. (2003) Type J CBFbeta/MYH11 transcript in the M4Eo subtype of acute myeloid leukemia. Hematology, 8, 115-117.
162. Tse, K-F., Mukherjee, G. & Small, D. (2000) Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia, 14, 1766-1776.
163. Ueda, S., Ikeda, H., Mizuki, M., Ishiko, J., Matsumura, I., Tanaka, H., Shibayama, H., Sugahara, H., Takai, E., Zhang, X., Machii, T. & Kanakura, Y. (2002) Constitutive activation of c-kit by the juxta-menbrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. International Journal of Hematology, 76, 427-435.
164. Valk, P.J.M., Bowen, D.I., Frew, M.E., Goodeve, A.C., Löwenberg, B. & Reilly, J.T, (2004) Second hit mutations in the RTK/RAS signalling pathway in acute myeloid leukemia with inv(16). Haematologica, 89, 106.
165. Van der Kolk, D.M., Vellenga, E., van der Veen, A.Y., Noordhoek, L., Timmer-Bosscha, H., Ossenkoppele, G.J., Raymakers, R.A., Muller, M., van Den Berg, E. & de Vries, E.G. (2000) Deletion of the multidrug resistence protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. Blood, 95, 3514-3519.
166. Van der Reijden, B.A., Lombardo, M., Dauwerse, H.S., Giles, R.H., Mulhematter, D., Bellomo, M.J., Wessels, H.W., Beverstock, G.G., Van Ommen, G.J.B., Hagemeijer, A. & Breuning, M.H. (1995a) RT-PCR diagnosis of patients with acute non-lymphocytic leukemia and inv(16)(p13;q22) and identification of new alternative splicing in CBFβ-MYH11 transcripts. Blood, 86, 277-282.
167. Van der Reijden, B.A., Martinet, D., Dauwerse, H.G., Giles, R.H., Wessels, H.W., Beverstock, G.G., Smit, B., Jotterand-Bellomo, M., Mühlematter, D., Lafage-Pochitaloff, M., Reiffers, J., Bilhou-Nabera, C., Van Ommen, G.J.B., Hagemeijer, A. & Breuning, M.H. (1995b) Simple method for detection of MYH11 DNA rearrangements in patients with inv(16)(p13q22) and acute myeloid leukemia. Leukemia, 10, 1459-1462.
168. Van der Reijden, B.A., Dauwerse, H.G., Giles, R.H., Jagmohan-Changur, S., Wijmenga, C., Liu, P.P., Smit, B., Wessels, H.W., Beverstock, G.G., Jotterand-Bellomo, M., Martinet, D., Muhlematter, D., Lafage-Pochitaloff, M., Gabert, J., Reiffers, J., Bilhou-Nabera, C., van Ommen, G.J., Hagemeijer, A. & Breuning, M.H. (1999) Genomic acute myeloid leukemia-associated inv(16)(p13q22) breakpoints are tightly clustered. Oncogens, 18, 543-550.
169. Van der Reijden, B.A., de Wit, L., van der Poel, S., Luiten, E.B., Lafage-Pochitaloff, M., Dastugue, N., Gabert, J., Lowenberg, B. & Jansen, J.H. (2001) Identification of a novel CBFB-MYH11 transcript: implications for RT-PCR diagnosis. Hematology Journal, 2, 206-209.
170. Wang, I., Saunthararajah, Y., Redner, R.L. & Liu, J.M. (1999) Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AMU-ETO leukemia cells. Cancer Research, 59, 2766-2769.
171. Wang, S.W. & Speck, N.A. (1992) Purification of core-binding factor, a protein that binds the conserved core site in murine leukemia virus enhancers. Molecular Cell Biology, 12, 89-102.
172. Wang, Q., Stacy, T., Miller, J.D., Lewis, A.F., Gu, T.L., Huang, X., Bushweller, J.H., Boories, J.C., Alt, F.W., Ryan, G., Liu, P.P., Wynshaw-Borris, A., Binder, M., Marin-Padilla, M., Sharpe, A.H. & Speck, N.A. (1996a) The CBFbeta subunit is essential for CBFalpha2 (AMLI) function in vivo. Cell, 87, 697-798.
173. Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A.H. & Speck, N.A. (1996b) Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 93, 3444-3449.
174. Wargnier, A., Legros-Maida, S., Bosselut, R., Boutge, J.F., Lafautie, C., Ghysdael, C.J., Sasportes, M. & Paul, P. (1995) Identification of human granzyme B promoter regulatory elements interacting with activated T-cell-specific proteins: implications of Ikaros and CBF binding sites in promoter activation. Proceedings of the National Academy of Sciences of the United States of America, 92, 6930-6934.
175. Wessels, H.W., Dauwerse, H.G., Breuning, M.H. & Beverstock, G.C (1991) Inversion 16 and translocation (16;16) in ANLL M4eo break in the same subregion of type short arm of chromosome 16. Cancer Genetics Cytogenettcs, 57, 225-228.
176. Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., Carrol, A.J., Mrozek, K., Vardiman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. & Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 7233-7239.
177. Wiemels, J.L., Xiao, Z., Büffler, P.A., Maia, A.T., Ma, X., Dicks, B.M., Smith, M.T., Zhang, L., Feusner, J., Wiencke, J., Pritchard-Jones, K., Kempski, H. & Greaves, M. (2002) In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukaemia. Blood, 99, 3801-3805.
178. Wijmenga, C., Gregory, P.E., Hajra, A., Schrock, E., Ried, T., Eils, R., Liu, P.P. & Collins, F.S. (1996). Core binding factor beta-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells. Proceedings of the National Academy of Sciences of the United States of America, 93, 1630-1635.
179. Wong, H.N., Ng, M.H.L., Huang, D.P. & Lee, J.C.K. (2000) Aberrant p 15 promotor methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood, 95, 1942-1949.
180. Wong, K.F. & Kwong, Y.L. (1999) Trisomy 22 in acute myeloid leukemia: a marker for myeloid leukemia with monocytic features and cytogenetically cryptic inversion 16. Cancer Genetics and Cytogenetics, 109, 131-133.
181. Yamamoto, K., Nakamura, Y., Saito, K. & Furusawa, S. (2000). Expression of the NUP98/HOXA9 fusion transcript in the blast crisis of Philadelphia chromosome positive CML with t(7;11)(p15;p15). British Journal of Haematology, 109, 423-426.
182. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R. & Naoe, T. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97, 2434-2439.
183. 1 cooperates with core binding factor β-smooth muscle myosin heavy chain to induce acute leukemia in mice. Cancer Research, 62, 2232-2235.
184. Yi, T.L., Cleveland, J.L. & IhIe, J.N. (1992) Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Molecular and Cellular Biology, 12, 836-846.
185. Yuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C.J., Burel, S.A., Lagasse, E., Weissman, I.L., Akashi, K. & Zhang, D.E. (2001) AML1-ETO expression is directly involved in the development of acute myeloid leukemias in the presence of additional mutations. Proceedings of the National Academy of Sciences of the United States of America, 98, 10398-10403.
186. Zent, C.S., Mathieu, C., Claxton, D.F., Zhang, D.E., Tenen, D.G., Rowley, J.D. & Nucifora, G. (1996) The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoting properties. Proceedings of the National Academy of Sciences of the United States of America, 93, 1044-1048.
187. Zhang, Y., Emmanuel, N., Kamboj, G., Chen, J., Shurafa, M., Van Dyke, D.L., Wiktor, A. & Rowley, J.D. (2004) PRDX4, a member of the peroxiredoxin family, is fused to AML (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22). Genes, Chromosomes and Cancer, 40, 365-370.
188. Zheng, R., Friedman, A.D., Levis, M., Li, L., Weir, E.G. & Small, D. (2003) internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBP(alpha) expression. Blood, 103, 1883-1890.